Tenofovir and lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus in highly viremic mothers in Vietnam

Nguyen Van Bang

##plugins.themes.vojs.article.main##

Tóm tắt

Objective. We evaluated effect and safety of lamivudine and tenofovir in late pregnancy
for preventing perinatal transmission of hepatitis B virus (HBV) to infants born to highly
viremic mothers in view of searching a rational regimen to control this transmission pathway
that perpetuates the infection in highly endemic region. Population and methods. Analysis
population consisted of 82 mother-child pairs who completed the study protocol. Pregnant
chronic HBsAg(+) women with high viremia (>107


copies/mL) at 32 weeks of gestation were
randomly located in 2 groups (lamivudine 100mg or tenofovir 300mg daily for 8 weeks of
prepartum to week 4 pospartum). At birth infants received recombinant HBV vaccine without
HBIg and were followed until week 52. Mother-to-child perinatal transmission was defined by
the presence of HBsAg in serum at week 52. Results. A sharp decrease of mean maternal viral
load from 5.09 x 108 ± 3.19 x 108 copies/mL at week 32 of gestation to 1.13 x 106


± 3.91 x 106
at labor (p<0.001) with undetectable HBV DNA in 2 cases (2.3%) was noted. The viral load
reduction was stronger in tenofovir-treated mothers than in lamivudine-treated ones (p<0.028),
particularly in 4 log10 reduction (p<0.001). At birth, HBsAg was positive in 21/82 (25.6%) and
HBV DNA detectable in 7/82 newborns (8.5%), without significant difference between two
groups of infants regardless of their mothers under lamivudine or tenofovir (p=0.075 and 0.591,
respectively). At week 52, HBsAg and HBV DNA was present in serum of 2/82 infants (2.4%).
Conclusion. Both tenofovir and lamivudine in late pregnancy showed the same safety and
effect of repressing HBV replication, and strikingly reduced perinatal transmission of HBV to
infants born to highly viremic mothers. From the point of view of cost-effectiveness, a priority of
lamivudine use in this situation seems more rational in low-income nations.

##plugins.themes.vojs.article.details##

Tài liệu tham khảo

1. WHO (2002). Hepatitis B. WHO/CDS/CSR/LYO/2002.2: Hepatitis B. http://www.who.int/emc.
2. Nguyen VT, Mc Laws ML, Dore GJ (2007). Highly endemic hepatitis B infection in rural
Vietnam. J Gasroenterol Hepatol 22(12): 2093-100.
3. Dusheiko G (2012). Interruption of mother- to-infant transmission of hepatitis B: time to
include selective antiviral prophylaxis? Lancet 379: 2019-2021.
4. Jonas MM (2009). Hepatitis B and pregnancy: an underestimated issue. Liver Int 29
(Suppl. 1): 133-139.
5. Umar M, Hamama-Tul-Bushra, Umar S, Khan HA (2013). HBV perinatal transmission. Int J
Hepatol 2013:875791. Epub 2013 Apr 22.
6. Wiseman E, Fraser MA, Holden S, Glass A, Kidson BL et al (2009). Perinatal transmission of
hepatitis B virus: an Australian experience. Med J Aust 190(9): 489-492.
7. Xiao XM, Li AZ, Chen X, Zhu YK, Miao J (2007). Prevention of vertical hepatitis B transmission by hepatitis B immunoglobulin in the third trimester of pregnancy. Int J Gynaecol Obstet 96(3): 167-170. Epub 2007 Feb 12.
8. Xu Q, Xiao L, Lu XB, Zhang YX, Cai X et al (2006). A randomized controlled clinical trial:
interruption of intrauterine transmission of hepatitis B virus infection with HBIG. World J
Gastroenterol 12(21): 3434-3437.
9. Xu WM, Cui YT, Wang L, Yang H, Liang ZQ et al (2009). Lamivudin in late pregnancy
to prevent perinatal transmission of hepatitis B virus infection: a multicenter, randomized,
double-blind, placebo-controlled study. J Viral Hepatitis 16: 94-103.
10. Deng M, Zhou X, Gao Sh, Yang SG, Wang B, Chen HZ, Ruan B (2012). The effects
of telbivudine in late pregnancy to prevent intrauterine transmssion of the hepatitis B virus: a
systemic review and meta-analysis. Virol J 9: 185. Published on line Sept 4, 2012 doi: 10.1186/1743-442X-9-185.
11. Han L, Zhang HW, Xie JX, Zhang Q, Wang HY, Cao GW (2011). A meta-analysis of
lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J
Gastroenterol 17(38): 4321-4333.
12. Han GR, Cao MK, Zhao W, Jiang HX, Wang CM et al (2011). A prospective and open-label
study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal
transmission of hepatitis B virus infection. J Hepatol 55(6): 1215-1221.
13. Pan CQ, Han GR, Jiang HX, Zhao W, Cao MK et al (2012). Telbivudine prevents vertical
transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol
10(5): 520-526.
14. Shi Z, Li X, Ma L, Yang Y (2010). Hepatitis B immunoglobulin injection in pregnancy to interrupt hepatitis B virus mother-to-child transmission: a meta-analysis. Int J Infect Dis 14(7): e622-34. Epub 2010 Jan 27.
15. Shi Z, Yang Y, Ma L, Li X, Schreiber A (2010). Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systemic and meta-analysis. Obstet Gynecol 116(1): 147-157.
16. Su GG, Pan KH, Zhao NF, Fang SH, Yang DH, Zhou Y (2004). Efficacy and safety of lamivudine
treatment for chronic hepatitis B in pregnancy. World J Gastroenterol 10(6): 910-912.
17. Tran TT (2009). Management of hepatitis B in pregnancy: Weighing the options. Cleveland
Clin J Med 76 (Suppl 3): S25-S29.
18. Van Nunen AB, de Man RA, Heijtink RA, Niester HGM, Schaml SW (2000). Lamivudine
in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic
hepatitis B patients. J Hepatol 32: 1040-1042.
19. Van Zonneveld M, van Nunen AB, Niesters HGM, de Man RA, Schalm SW and Janssen HLA
(2003). Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B
virus infection. Journal of Viral Hepatitis 10: 294-297.
20. Li XM, Yang YB, Hou HY et al (2003). Interruption of HBV intra-uterine transmission:
a clinical study. World J Gastroenterol 9(7): 1501- 161503.
21. Nie R, Jin L, Zhang H, Xu B, Chen W, Zhu G (2011). Presence of hepatitis B virus in
oocytes and embryos: a risk of hepatitis B virus transmission during invitro fertilization. Ferlitity
and Sterility 95 (5): 1667-1671.
22. Antiretroviral Pregnancy Registry St eering Committee (2008). Antiretrovital
pregnancy reistery international interim report for 1 January 1089 through 31 July 2008. Wilm-
ington, NC: Registry Coordinating Center, 2008. Antiretroviral Pregnancy Registery Web site
http://www.apregistry.com/forms/interim_re-port.pdf. Accessed December 17, 2008.